Dry eye disease is prevalent in Hong Kong. Up to 70% of elderly patients greater than 60 years of age are su�ering from symptomatic dry eye disease, having gri�y and painful eyes, with associated blurred vision. One common cause of dry eye disease is meibomian gland dysfunction (MGD), which is a condition with insu�cient lipid secretion from meibomian gland, undermining tear film stability and producing dry eye symptoms despite normal tear secretion. Intense pulsed light (IPL) therapy, which uses light energy on the skin surface, is widely used in dermatology to treat a variety of conditions including dermal vascular lesions, such as port wine stains and hemangiomas, facial rosacea, and acne. Since April 2021, IPL is a United States Food and Drug Administration (US FDA)-approved treatment for dry eye disease due to MGD. The Department of Ophthalmology has been optimizing treatment se�ings of IPL therapy in Asian populations and extending its indications to other forms of dry eye disease, including those related to Sjogren’s syndrome and prolonged topical glaucoma medication use. 乾眼症在香港是常見的眼科疾病之一。六十歲 以上的老年患者更有高達百分之七十患有乾眼 症,眼睛會感到刺痛和視力模糊。乾眼症的其中 一個常見原因是瞼板腺功能障礙(MGD),這是 一種瞼板腺分泌脂質不足的疾病,儘管淚液分泌 正常,但會破壞淚膜穩定性並產生乾眼症症狀。 在皮膚表面使用光能量的強脈衝光(IPL)療法, 正廣泛使用於皮膚科治療各種疾病,包括皮膚血 管病變,例如鮮紅斑痣和血管瘤、面部紅斑痤瘡 和痤瘡。自2021年4月以來,美國食品和藥物管 理局(US FDA)批准利用IPL來治療由MGD引起 的乾眼症。香港大學眼科學系一直致力優化針 對亞洲人群組的IPL治療,並將其應用範圍擴展 至其他形式的乾眼症,包括與乾燥綜合徵和長期 局部青光眼藥物使用相關的乾眼症。 27 HKU Eye Center Inaugural Report The University of Hong Kong